PeptideSearch

Vesugen

Animal studies only

Get notified when the evidence changes.

Almost all the research is in animals. We do not know if the same thing happens in people.

Compiled and reviewed by the PeptideSearch Editorial Team · Status checked 2026-08-04

Also called Lys-Glu-Asp

A three-part peptide from Russian research, studied in animals for blood vessel tissue.

Official status: Not nominated for 503A compounding · Checked 2026-08-04

Can a doctor prescribe this?

Small pharmacy (503A)
Never put forward to FDA
Large outsourcing facility (503B)
Never put forward to FDA

Not FDA approved and not on the U.S. compounding list. A doctor cannot prescribe it.

503A is a pharmacy making a single prescription for one patient. 503B is a facility making batches. They are governed by separate lists. Where a category is shown, it is a position on the FDA's list of substances that have been put forward and are still being worked through — not the final list, which is set by rulemaking. Category 1 means the FDA does not plan to act against a pharmacy that makes it while the review runs.

Lab suppliers we list: 4

Doses used in research

Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.

No dosing information has been published in the research indexed here.

Spot an error? corrections@peptidesearch.org

We'll email you when a new study, trial or status change lands for Vesugen. Unsubscribe in one click.